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INTRODUCTION 
 
 
 
Chronic Kidney Disease (CKD) is a global threat to health in 
general and for developing countries in particular because therapy is 
expensive and life long.1 
CKD, encompasses a spectrum of different pathophysiological 
processes associated with abnormal kidney function and a progressive 
decline in Glomerular Filtration Rate (GFR).2 
CKD usually has a gradual onset and in many cases progresses 
inexorably to a critical state – end stage renal disease (ESRD), in 
which the patient’s survival requires the initiation of renal replacement 
treatment, either by dialysis or renal transplantation.3 
The prevalence of CKD  is  increasing  among the different 
population of the world. According to various studies, the incidence 
and prevalence of CKD in India is ~ 0.78%.4 The domiciliary 
screening programme for CKD in South India has reported the 
prevalence of CKD (Stage 5) as 870 per million population (pmp)5. 
CKD with its multitude of complications and devastating 
outcomes leads to a significantly higher risk for Cardiovascular 
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Disease (CVD) and all cause mortality in an individual 6. Kidney 
disease is both a cause and consequence of  Cardiovascular Disease. 
All CKD patients irrespective of the underlying  etiology, are at 
increased risk of CVD including coronary heart disease, 
cerebrovascular disease, peripheral  vascular disease and heart failure. 
From the mortality stand point, it is not progression to kidney failure 
is more concerning in CKD patients, but progression to CVD6. 
CVD is the leading cause of morbidity and mortality in patients 
at every stage of CKD2. Thus a focus of patient care in  CKD   should  
be directed to the prevention of Cardiovascular complications, in 
which atherosclerotic narrowing of vessels plays a major role. 
Several articles have revealed a fact that decreased levels of 
High Density Lipoprotein (HDL) & Paraoxonase (PON) activity in 
CKD  patients are being the risk factors for the development of CVD. 7 
PON, an aryl dialkyl phosphatase which reversibly binds & 
hydrolyzes  organophosphates is synthesized in the liver  , resides over 
HDL and has both antioxidant and antiatherogenic functions. The role 
of  PON in the development of CVD has drawn considerable attention 
in the recent years. 7,8 
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PON prevents atherogenesis by protecting the LDL against 
peroxidation and by inhibiting the monocyte – endothelial interactions 
in the inflammatory response of vascular endothelial cells. 9,10 
Thus, estimation of PON activity in  CKD patients is being 
valuable in predicting atherosclerosis and of future cardiovascular 
events. This study aims at establishing the role of PON as an 
antiatherogenic agent in CKD patients. 
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AIM & OBJECTIVE 
 
 
 
The aim of this study is to determine the Serum PON activity in  
CKD patients and to compare the results with the healthy control 
subjects. 
 
The objective of this study is - 
to  analyze the  Serum PON  activity and  Lipid profile  in  
CKD patients for  predicting the atherogenic risk  in these 
patients & to  intervene  earlier in preventing Cardiovascular 
complications. 
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REVIEW OF LITERATURE 
 
The kidneys being the major excretory organs in human with a 
high degree of structural complexity excrete the waste products of 
metabolism, precisely  regulating  the  body’s concentration of  salt 
and water, maintain the appropriate acid balance of plasma and serve 
as an endocrine organ, secreting such hormones as erythropoietin, 
renin and prostaglandin.11 
Diseases of the kidneys are as complex as its structure. The 
chronic kidney disease represents the entire spectrum of disease that 
occurs following the initiation of kidney damage. 
DEFINITION OF CKD  
According to the National  Kidney  Foundation :- 
    CKD is defined as the presence of objective kidney damage and / or 
the presence of a GFR of 60 ml / min / 1.73 m2 body surface area or 
less, for  atleast 3 months irrespective of the underlying etiology of the 
kidney damage. 12 
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The severity of the resulting syndrome is denoted by a staging 
scheme that extends from occult kidney damage, with well-preserved 
function (Stage 1) down to the level of kidney failure requiring renal 
replacement therapy (Stage 5). 12 
 The stages of CKD are given in the Table - 1 
The term ESRD – represents a stage of CKD where the 
accumulation of  toxins, fluid and electrolytes (normally excreted  by 
the  kidney)  results  in uremic syndrome. This expression ESRD is 
used to represent those subjects receiving or eligible for renal 
replacement therapy either by some form of dialysis or by 
transplantation. 
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EPIDEMIOLOGY 
The frequency of CKD continues to increase worldwide13. The 
incidence of CKD has doubled in the last 15 years.1 
The  reported  prevalence  of CKD  Stages 1-4 in the most 
recent  NHANES (National Health and Nutrition Examination Survey) 
between 1999-2006  was  26 million (13%) out of ~ 200 million 
United States  residents  aged  20 and older. Of  these  65.3% had 
CKD    Stage  3-4. 
The most recent report of the United States Renal Data System 
estimates that nearly one half million patients in the US were treated 
for ESRD in the year 2004,  and  at the end of 2010 ,this figure is 
expected to increase by ~ 40%.13 
 
CKD IN INDIA 
In the most representative population based study from North 
India, using a multistage cluster sampling technique, prevalence of 
CKD  in India is ~785 pmp and the incidence of ESRD is ~ 150 pmp.4 
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The domiciliary screening programme for CKD by a trust in 
South India  has reported the prevalence of CKD Stage 5 to be 0.87 
per thousand (870 per million). 5 
 ETIOLOGY 
CKD may be caused by any condition which destroys the 
normal structure and function of the kidney. The common causes are 
1) Congenital & Inherited 
2) Renal artery stenosis 
3) Hypertension 
4) Glomerular diseases 
5) Interstitial diseases 
6) Systematic inflammatory diseases 
7) Diabetes mellitus.14 
RISK FACTORS  
These factors increase the risk of CKD even in individuals with 
normal GFR. Among the strongest factors associated with increased 
risk for CKD are the  Diabetes  and Hypertension. 
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Additional Risk Factors are  
1) Autoimmune disease 
2) Chronic systemic infection 
3) Cancer 6 
4) Family History 
5) Reduced renal mass 
6) Low birth weight 
7) Drug exposure 
8) Urinary tract infection 
9) Structural abnormalities of urinary tract 
10) Previous episode of Acute renal failure 2 
11) Older age 
12) Ethnicity. 
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PATHOPHYSIOLOGY OF CKD 
The pathophysiology of CKD involves 2 broad sets of 
mechanisms of damage. 
i) Initiating mechanisms are specific to the underlying 
etiology. (eg) Immune complexes and mediators of 
inflammation in certain types of  glomerulonephritis or 
toxin exposure in certain diseases of renal tubules and 
interstitium. 
ii) A set of progressive mechanisms, involving hyper 
filtration and hypertrophy of the remaining viable 
nephrons, that are a common consequence following long 
term reduction of renal mass, irrespective of underlying 
etiology. 
Eventually the short term adaptations of hypertrophy and 
hyperfiltration  become maladaptive as the increased pressure and 
flow predisposes to sclerosis and drop out of remaining nephrons .2 
 
 
11

CLINICAL ABNORMALITIES IN CKD 
CKD leads to disturbances in the function of virtually every 
organ system. The disturbances are found in 
1. Cardiovascular and pulmonary system. 
2. Gastrointestinal system. 
3. Haematologic and immunologic functions. 
4. Neuromuscular System. 
5. Endocrine & metabolic functions.  
6. Fluid, Electrolyte & Acid base Balance. 
7. Dermatologic manifestation.15 
Among all these disturbances, the CVD is the leading cause of 
morbidity and mortality in patients of every stage of CKD.2 
CARDIOVASCULAR ABNORMALITIES IN CKD 
Cardiovascular abnormalities occur almost invariably when 
renal function  deteriorates . Hypertension, congestive heart failure, 
valvular stenosis or insufficiency and accelerated atheromatosis are 
among the most frequent epiphenomena. 16 
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The early stage of CKD, manifesting as albuminuria and even a 
minor decrement in GFR, is now recognized as a major risk factor for 
CVD. Thus most patients with CKD succumb to CVD before  
reaching stage 5 2. 
RISK  FACTORS  FOR CARDIOVASCULAR DISEASE IN 
CKD 
The increased prevalence of vascular disease in CKD patient 
derives  from  both  traditional  & non-traditional factors (CKD-
related risk factors). 
Traditional Factors 
• Hypertension 
• Hypervolemia 
• Dyslipidemia 
• Sympathetic overactivity 
• Hyperhomocysteinemia 
• Diabetes Mellitus 
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CKD related risk Factors 
• Anemia 
• Hyperphosphatemia 
• Hyperparathyroidism 
• Dyslipidemia 
• Uremic toxins 
• Proteinuria 
• Oxidative stress 
• Elevated homocysteine 
• Generalized inflammation.17,18 
The inflammatory state associated with a reduction in kidney 
function is reflected in increased circulating acute phase reactants, and 
proinflammatory  agents  such as the cytokines, oxidation products,   
C-reactive protein and glycation products. These are considered as the 
main culprits in CVD 16. This inflammatory state appears to accelerate 
vascular occlusive disease. 
Atheromatosis has been classified as an inflammatory rather 
than a degenerative disease. In CKD, inflammation and CVD have 
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been linked to each other. Uremia induced atherogenic alterations 
probably start to take place much earlier in the course of CKD.16, 18 
ATHEROSCLEROSIS 
            Atherosclerosis, the leading contributor to coronary artery 
disease and cerebrovascular disease is a form of arteriosclerosis in 
which soft deposits of intra arterial fat and fibrin on the vessel walls 
harden over time. 
Atherosclerosis is not a single disease entity. It can take several 
forms, depending on the anatomic location, age, genetic and 
physiologic status and risk factors to which the individual is 
exposed.19 
PATHOGENESIS 
   Atherosclerosis  is  a complex disease  that involves 
lipoprotein  influx  and  modification, increased pro-oxidant stress and 
inflammatory angiogenic and fibroproliferative responses 
intermingled with Extracellular Matrix (ECM) and smooth muscle 
cells  proliferation  in the  vessel  wall  resulting  in the formation of 
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atherosclerotic plaque which  causes obstruction  of   the  blood  
vessels . 20 
The arterial smooth muscle cells, endothelial injury, blood 
monocytes and dyslipidemia are the four key factors involved in the 
origin and progression of the lesion of atherosclerosis. 
Currently pathogenesis of atherosclerosis is explained on the 
basis of 2 theories. 
 
1) Reaction to Injury Hypothesis 
The modified response to injury hypothesis was described by 
Ross in 1993. It implicates lipid entry into the intima of the vessel 
walls as the initial event , followed by lipid accumulation in the 
macrophages (foam cells), which according to the modified theory, are 
believed to be  the dominant cells in early lesions. 
 
2) Monoclonal Hypothesis 
This hypothesis is based on the postulate that proliferation of 
smooth muscle cells is the primary event in atherogenesis and this 
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proliferation is monoclonal in origin. This proliferation may be 
initiated by mutation caused by; 
     1. Exogenous chemical  (eg) Cigarette smoking. 
      2. Endogenous metabolites (eg) Lipoproteins. 
3. Some viruses    (eg) Marek’s disease virus in         
chicken herpes virus. 21 
Development of Atherosclerosis: 
Chronic endothelial injury due to toxins from smoking, 
hypertension, hyperlipidemia & hemodynamic disturbances lead to 
endothelial dysfunction causing increased permeability and 
accumulation of lipoproteins in the intima of the vessel walls.22, 23 
The oxidative modification of the accumulated plasma 
lipoproteins- Low Density Lipoprotein (LDL) and association with the 
proteoglycans occurs within the intima of the arteries forming fatty 
streak.2 The endothelial cells begin to express a Vascular Cell 
Adhesion Molecule (VCAM-1) on their surface, which binds precisely 
the monocyte and T-lymphocyte.  
17
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After monocytes adhere to the endothelium, they 
i) Migrate between ECM to localize in the intima, largely 
stimulated by chemokines .  
ii) Transform into macrophages and avidly engulf 
lipoprotein, largely oxidized LDL via scavenger 
receptors forming foam cells. 25 
Interleukin-I (IL-I),`Tumour  Necrosis  Factor  (TNF) and  
Monocyte Chemoattractant Protein–I (MCP-1) are produced by  
macrophages  and they increase the adhesion of leukocytes and recruit 
more of them into the plaque. Macrophages produce toxic oxygen 
species that also cause oxidation of the LDL in the lesions  and  they 
elaborate growth factors that may contribute to smooth muscle cell 
proliferation. Moreover  the activated leukocytes and vascular wall 
cells also release growth factors (26, 27) (like Platelet Derived Growth 
Factor, Fibroblast Growth Factor and Transforming Growth Factor), 
that promote smooth  muscle  cell  proliferation and  ECM  synthesis 
converting it to a mature atheroma and contribute to the progressive 
growth of atheromatous plaques, forming lesions.28,29 
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The Role of Lipids in Atherosclerosis 
• Hypercholesterolemia is by for the most important risk 
factor for atherosclerosis. It can cause plaque formation 
and its growth, in the absence of other known risk 
factors.30 
Genetic and acquired disorders that cause hypercholesterolemia 
lead to premature and severe atherosclerosis.21 
The evidences implicating hypercholesterolemia in the genesis 
of atherosclerosis includes the following. 
o The major lipids in the atheromatous plaques are plasma 
derived Cholesterol and Cholesterol Esters. 
o Oxidized LDL is observed in macrophages in arteries at 
sites of fatty streaks. 
o Genetic defects in lipoprotein metabolism causing 
hyperlipoproteinemia are associated with accelerated 
atherosclerosis. 
o Lowering levels of serum Cholesterol by diet or drugs 
slows the rate of progression of atherosclerosis, causes 
19

regression of some plaques and reduces the risk of 
cardiovascular events. 
•
 Dyslipoproteinemia resulting either from mutation that yield 
defective apolipoproteins or some other underlying disorders 
(for example CKD, Hypothyroidism or Diabetes Mellitus),25 can 
lead to atherosclerosis. 
LIPID ABNORMALITIES IN CKD 
Patients with CKD suffer from a secondary form of complex 
dyslipidemia consisting of both qualitative and quantitative 
abnormalities in serum lipoproteins resulting from alteration in 
lipoprotein metabolism and composition 31. 
The prominent features of uremic dyslipidemia are ; 
1) A profound defect in postprandial lipid disposal, which exposes     
the vasculature to high Chylomicron remnant concentration.15 
2) Increase in Serum Triglycerides (TGL) [due to increased Very Low 
Density Lipoprotein (VLDL) remnants & Intermediate Density 
Lipoprotein (IDL) ] and low HDL. 31 
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3)   Increased heterogeneity of LDL and HDL apoproteins. 15 
4)  Serum LDL is mostly normal but the Cholesterol may originate 
from the atherogenic  small and dense LDL subclass(sdLDL) .31 
5) Increased LDL susceptibility to oxidation. 
6) Altered cell surface LDL epitope and recognition.  
7) The apolipoprotein-B (apo B ) containing part of lipoprotein 
may undergo modifications. [Enzymatic and Advanced 
Glycation End Product (AGE) peptide modification, oxidation 
or glycosylation]. These modifications contribute to the 
impaired LDL-receptor mediated clearance from plasma and 
promote prolonged circulation. 
8) HDL maturation is impaired and its composition is altered. The 
antioxidant and anti-inflammatory functions of HDL are 
depressed.32The  defect in HDL maturation is largely caused by 
acquired Lecithin Cholesterol Acyl Transferase (LCAT) 
deficiency while its TGL enrichment is due to Hepatic Lipase 
deficiency.33 
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ACCELERATED ATHEROGENESIS IN CKD 
In CKD there is an impaired clearance and accumulation of 
oxidation  prone VLDL and Chylomicron remnants and abnormal 
LDL composition leading to oxidative stress and inflammation 
favouring  their  uptake by macrophages and resident cells in the 
artery wall. 33 
While  LDL particles undergo vicious cycle of accumulation 
and  modification, reverse   cholesterol transport is also impaired due 
to low LCAT and PON activity.31 
Therefore, the discoid HDL particles are structurally altered and  
hepatic cholesterol clearance is limited. Thus in CKD, there is an 
accelerated  atherogenesis due to the effect of heightened influx of 
lipids compounded  by impaired HDL-mediated reverse cholesterol 
transport  leading to foam cell formation which is the central event in 
atherosclerosis plaque formation.33 
 
 
 
22

ATTENUATION OF ATHEROSCLEROSIS 
            Protection of LDL against oxidation by antioxidants can 
contribute to the attenuation of atherosclerosis. (34,35,36,37)   
They can act  ; 
1. Directly on the LDL 
2. Indirectly on the cellular oxidative machinery 
3. By converting oxidized LDL to a non-atherogenic particle 
by HDL-associated PON I                                 
                   
            The ability of HDL to inhibit the oxidation of LDL and 
promote macrophage cholesterol efflux  is  also through the action of 
several of its associated proteins, particularly PON I which reduces 
the inflammation associated with atherosclerosis.(38) 
PARAOXONASE (PON) 
PON  is an aryl dialkyl phosphatase . E.C. 3.1.8.1. 
          PON is a multifunctional antioxidant enzyme component of 
HDL,   which can protect LDL against  oxidation.39  PON  is a serum 
arylesterase  that was initially identified by its hydrolysis of aromatic 
carboxylic esters and organophosphorus insecticides and nerve 
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agents.40,41Its name reflects its ability to hydrolyze paraoxon, a 
metabolite of insecticide parathion. 
Serum PON I and perhaps other mammalian Paraoxanases, act 
as important guardian against cellular damage from toxic agents, such 
as organophosphates, oxidized lipids in the plasma LDL and bacterial 
endotoxins (42, 43). There are three members in the PON gene family. 
1) PON 1 
• It is synthesized in the liver & transported along with HDL in 
the plasma. 
• Its serum concentration is influenced by the inflammatory 
changes. (44, 45, 46, 47) 
2) PON 2 
It is a ubiquitously expressed intracellular protein, which can 
protect the cells from oxidative damage (such as cells of arterial wall 
& macrophages) and may not be associated with lipoprotein. (48, 49) 
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3) PON 3 
• It is similar to PON I, but differs from its substrate specificity. 
• It lacks paraoxon and phenyl acetate hydrolyzing activity. 
• It is not regulated by  inflammation  & by the levels of oxidized 
lipids 44. 
 
PON 1, 2&3, genes are aligned next to each other on the long arm of 
chromosome 7 (7q 21.3-22.1) 50All the members of the PON gene 
family share ~65% similarity at the amino acid level.51 
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PON I 
PON I  is  the  most studied of all the members of PON family. 
It is a glycoprotein with a MW of 38 kDa and 354 Amino acids 
encoded by the PON-1 gene, which maps to the human chromosome 
7q, 21-22. 51,52 
There are 2 common PON 1 gene coding polymorphisms  
1)PON 1 Q 192 R   
2)PON 1 L 55 M 
The  first polymorphism  differ in the aminoacid at position 
192. (glutamine & arginine)The second polymorphism differ in the 
aminoacid at position 55 (methionine and leucine) 53,54,55 
PON I is synthesized in the liver and transported primarily on 
apolipoprotein A-1(apoA-1) containing HDL56. The secreted protein 
retains its hydrophobic leader sequence, which is a structural 
requirement for PON’s association with HDL 46,57 
In addition to the presence of PON 1 mainly on HDL, 
postprandial Chylomicrons  also contain minor, but significant amount 
of PON 1.PON 1 was also detected in VLDL but not in LDL.58 
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PON & HDL 
PON activity is highest in the more dense HDL 3  fraction, 
where PON I was not dissociated from these particles even during 
centrifugation.59 
Using the immuno affinity chromatography, a subclass of HDL 
containing  apoA-I  apo J and PON was obtained. Thus PON has been 
isolated from human plasma in association with apoA-I and with         
apo J. 60, 61 
Structure of PON I 
The first crystal structure of PON I was obtained by direct 
evolution, at a resolution of 2.2Ao 
PON I  is a six-bladed  Beta-propeller, with an unique active 
site lid that is also involved in HDL binding.62,63 
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REGULATION OF PON-ACTIVITY 
Genetic Factors 
PON 1 gene is regulated by SP I and Protein kinase C, whereas 
PON 2 gene in macrophages is regulated by NADPH oxidase. 64,65 
Non-genetic factors   
 A variety of non-genetic factors have been shown to influence 
PON 1 levels such as diet, smoking, acute phase reactants and 
hormones. Nutritional  antioxidants such as polyphenols, increase 
PON I  mRNA expression and activity by an aryl hydrocarbon  
receptor dependent mechanism.49PON 1 levels are influenced by a 
variety of environmental factors including statins & cytokines66In 
human, consumption of degraded cooking oil 67 lowered the PON1 
level, while alcohol 68 and Vitamin C& E elevated it.69 
FUNCTIONS OF PON 
1) Paraoxonases(PONS) metabolize 5- hydroxy eicosatetraenoic 
acid and 1,5 – lactone, & 4-hydroxy docosa hexaenoic acid, 
which are the products of both enzymatic and non-enzymatic 
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oxidation of arachidonic acid and docosa hexaenoic acid 
respectively and may represent PON’s endogenous substrates. 
2) PON I  hydrolyzes the toxic oxon metabolites of a number of 
organophosphorus insecticides such as parathion, diazinon and 
chlorpyrifos and even nerve agents such as sarin and soman. 
3) The bulky drug substrates like lovastatin and spironolactone are 
hydrolyzed only by PON 3 70 
4) The PONS catalyze the hydrolysis of variety of aromatic and 
aliphatic lactones as well as the reverse reaction, lactonization 
of  and  -hydroxy carboxylic acid .71,72,73 
5) PON I degrades bioactive phospholipids such as platelet 
activating factor, thereby preventing intravascular coagulation.74 
6) PON protects lipids in lipoprotein, in macrophages and in 
erythrocytes from oxidation 65. 
7) PON increases the HDL binding to macrophages which in turn 
stimulates  HDL’s ability to promote cholesterol efflux and also 
inhibits Cholesterol biosynthesis (74, 75, 38) 
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8) PON was shown to increase the breakdown of specific oxidized 
lipids in oxidized LDL(ox-LDL) and decrease the macrophage 
uptake of ox-LDL 65 
9) PON attenuates the ox-LDL induced MCP-I production by 
endothelial cells. 76 
 
 
 
 
 
 
 
 
 
 
 
 
30

PON & ATHEROSCLEROSIS 
PON 1 is inactivated under oxidative stress75. PON activity may 
also be altered as a part of inflammatory response77 and it is evident 
by the fact that the HDL became proinflammatory during the acute 
phase response, possibly due to  the loss of  PON I activity from HDL. 
The inactivation of PON I reduces the ability of HDL to inhibit 
LDL modifications and monocyte endothelial interactions. Since both 
these mechanisms are important in the inflammatory response of 
arterial wall cells, atherogenesis is favoured. 78, 79 
The PON is involved in hydrolysis of homocysteine thiolactone 
into homocysteine (thiolactonase activity). Thus, decrease in PON 
activity may initiate a positive feedback mechanism causing further 
accumulation of homocysteine thiolactone, which can damage protein 
by homocysteinylation of the lysine residues, which are auto-
immunogenic and  prothrombotic  leading to atherosclerosis. 38,80 
PON involvement in the pathogenesis of atherosclerosis is 
suggested by the increasing PON I immunoreactivity in the arterial 
wall as the atheroma advances.54 
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Thus, PON I confers protection against coronary artery disease 
by inactivating and removing the pro-inflammatory lipid oxidation 
products from the carotid and coronary plaques. 81, 82 
 
PON IN CKD 
Decreased PON activity in CKD can be due to decreased HDL 
concentration & also due to the uremic environment. In uremic 
environment, the PON activity is inhibited through the post-
translational modification of PON as a result of reactions with 
Advanced Glycation End Products and Urea derived cyanate. 
Due to the increased production of toxic free radicals, the 
efficiency to hydrolyze lipid peroxides by PON is decreased, which 
further decreases its specific activity. 
The decreased levels of PON and thus reduction of its 
antiatherogenic activity in CKD could be an essential factor of 
premature vascular aging leading to Cardiovascular complications. 
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MATERIALS AND METHODS 
The study was done after obtaining the approval from the 
Ethical Committee of Stanley Medical College & Hospital. 
This is an age and sex matched study. Hundred subjects were 
chosen for the study. Both males and females in the age group of          
15-75 yrs were included and an informed consent was obtained from 
all of them. The study population includes 2 groups: 
Group I : Consists of 50 healthy subjects with normal clinical 
& biochemical parameters. They were selected from 
the Master Health check up ,Outpatients department 
of Stanley Medical College & Hospital. 
Group II: Consists of 50 patients with Chronic Kidney 
Disease. They were selected from the Department of 
Nephrology, Stanley Medical College & Hospital. 
Inclusion Criteria 
Patients  with CKD. 
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Exclusion Criteria 
1) Patients with liver disease 
2) Patients with chronic infections 
3) Patients with Diabetes Mellitus 
4) Patients who are not willing to give informed consent. 
Sample Collection  
Fasting venous blood sample of 5ml was collected with strict 
aseptic precautions. 2 ml of the collected blood was transferred to the 
test tube containing anticoagulant for glucose estimation.3ml of the 
blood sample was transferred to a plain test tube. The samples were 
centrifuged, plasma  &  serum were separated respectively. The 
following parameters were estimated. 
1) Paraoxonase activity 
2) Total cholesterol 
3) HDL cholesterol 
4) TAG 
5) Creatinine 
6) Urea 
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7) Glucose 
8) Albumin 
LDL cholesterol and VLDL  cholesterol  levels were calculated.  
ESTIMATION OF SERUM PON ACTIVITY 
PON activity was estimated spectrophotometrically using  
Paraoxon (0,0-diethyl-0-4-nitro phenylphosphate) as the substrate for 
hydrolysis. 
The chemicals used were of analytical reagent grade from 
SIGMA chemicals. 
Principle 
Serum PON, hydrolyzes paraoxon in the presence of calcium  at 
pH 8.0  at   250C  and releases para-nitrophenol (p-NP).The liberated 
p-NP is measured and the activity of PON can be calculated using the 
molar absorption of p-NP in a kinetic assay. The absorbance was 
monitored at 405 nm .One unit (1U) of PON activity is defined as 1 
µmol of p-NP formed per min per litre at 250C and the activity was 
expressed  as U/L of serum. 
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              Paraoxon 
  O 
 
C2H5O   P O   NO2 
   
  OC2H5 
 
 
   H20 
   PON 1
 
  O 
 
C2H5O -  P OH  +  HO   NO2 
   
 
  OC2H5   Paranitrophenol 
 
 Diethyl phosphate    
 
 
 
Reagents : 
The assay mixture consisted of 2.2mM paraoxon substrate in 
0.1m Tris HCL buffer, pH 8.0 containing 2mm CaCl2. 
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Reagent Preparation 
Buffer : 
O.1M Tris 
12.114 gm of  Tris  is dissolved in 1000ml of  Distilled water 
(DW). 
O.1M HCL 
1 ml of 10 molar solution of HCL in 99ml of DW. 
2 mM CaC12 
294.04 mg of CaCl2 is dissolved along with Tris. 
To Prepare the Buffer: 
90ml of Tris solution with CaCl2 is taken and 0.1M HCl is 
added till the pH 8.0 is obtained. The buffer solution is refrigerated. 
Substrate Preparation 
2.2mM paraoxon is needed. To achieve this, 3 ml of the 
paraoxon is added to 6.355 ml of the buffer. This is freshly prepared. 
 
37

MOLAR ABSORPTIVITY OF PARA NITRO PHENOL 
The micromolar  absorptivity of p-NP was measured as follows; 
Molecular weight of p-NP = 139.11g /mole 
1 micromole    = 139.1 µg/L 
The amount is weighed and dissolved in the buffer and the 
absorption is read at 405 nm in the spectrometer. 
Absorbance = 0.026 
As per Beer’s law 
 A =  Σbc  A – Absorption 
     Σ - absorptivity 
  Σ = A  b – pathlength 
        bc  c – concentration of the substance 
Micromolar absorptivity 
 = 0.026  b = 1 cm  
      1x1  c = 1 µmol 
 = 0.026  
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Enzyme activity U/L = 
  (Delta absorbance / min )x Total Volume 
         Sample Volume x Micromolar Absorptivity x Pathlength 
 
Factor has been calculated  from the formula: 
  Total  Volume 
  Sample Volume×Micromolar Absorptivity×Pathlength 
=550   
 50×0.026×1 
=423 
   
Thus, Enzyme activity ( U/L )=  ∆ abs/min x 423.
 
PROCEDURE 
Assay Parameters 
Mode - Kinetic 
Wavelength - 405nm 
Sample volume - 50 µl 
Reagent volume - 500 µl 
39

Lag Time  -  60 sec 
Kinetic Interval  -  180 sec 
Number of readings -  3 
Factor -  423 
Reaction temperature  -  25 0C 
Reaction direction -  Increasing 
Units -  U/L 
Assay Procedure: 
500µl of the reagent and 50µl of the sample were taken, mixed 
well & read at 405nm using the semi auto analyzer MICROLAB 300. 
Reference Range : 90 – 150 U/L . 
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QUANTITATIVE ESTIMATION OF BLOOD UREA      
NITROGEN 
(UV KINETIC METHOD) 
Principle 
Urea was hydrolyzed in the presence of water and urease to 
produce ammonia and CO2. The  ammonia  produced combines with 
-Ketoglutarate(-KG ) and NADH in the presence of  glutamate 
dehydrogenase (GLDH) to yield glutamate & NAD. The amount of 
urea nitrogen may be calculated by determining the absorbance 
decrease per minute relative to urea nitrogen standard at 340nm. 
Reagents TRIS BUFFER          pH 7.55  – 75 m mol / L 
     GLDH  > 1000 U/L 
Urease  > 30,000 U/L 
NADH  – 0.32 mmol / L 
-KG  – 9 mmol 
Standard-50mg/dl 
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Procedure : 
10µl of sample was added to1 ml of reagent at 370C, mixed and read 
at 340nm. 
 
Reference values :   6-20 mg/dl. 
QUANTITATIVE ESTIMATION OF SERUM CREATININE                       
(BY MODIFIED JAFFE’S METHOD) 
Principle 
Creatinine present in the sample reacts with picric acid in 
alkaline medium and forms creatinine picrate (red colored complex) 
which is measured at 490 nm.The intensity of the coloured complex is 
directly proportional to the concentration of the creatinine in the 
sample. 
 
 Blank Std Test 
Reagent 1ml 1ml 1ml 
Std  10µl  
Sample   10µl 
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Reagents  
Saturated picric acid          10 ml 
0.75N Sodium hydroxide  10 ml 
Standard 2mg/ dl. 
Procedure 
100µl of sample was added to 1 ml of reagent at 370C, mixed 
and read at 490 nm . 
 Blank Std Test 
Reagent 1ml 1ml 1ml 
Std - 100µl - 
Sample - - 100µl 
 
Reference values  : 0.8 – 1.2 mg/dl 
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ESTIMATION OF TOTAL CHOLESTEROL 
The tests were performed in the reagent kit by ENZYMATIC 
CHOLESTEROL ESTERASE METHOD. 
Principle 
The free cholesterol liberated from the cholesterol esters by 
cholesterol esterase is oxidized by cholesterol oxidase to cholestenone 
with the simultaneous production of hydrogen peroxide. The hydrogen 
peroxide reacts with 4 aminoantipyrine and a phenolic  compound in 
the presence of peroxidase to yield a red coloured complex. 
Cholesterol ester +H2O  Cholesterol esterase   Cholesterol + Fatty acid 
Cholesterol + O2        Cholesterol Oxidase   Cholestenone + H2O2  
 
H2O2 +4 amino antipyrine + Phenolic compound 
                             Peroxidase      Quinoneimine dye + H2O 
The concentration of cholesterol in the sample is directly 
proportional to the intensity of the red coloured complex which is 
measured at 500nm. 
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Reagent : 
Reagent 1 (Enzyme / chromogen) 
Reagent 1A (Buffer) 
Cholesterol  Standard -200mg/dl 
Reconstituted Reagent : 
Dissolve the contents of one bottle of reagent I with one bottle 
of reagent 1A. 
Procedure 
 Blank Std Test 
Reagent 1ml 1ml 1ml 
Std - 100µl - 
Sample - - 100µl 
 
Incubate for 5 min at 370C , absorbance is  read at 500nm. 
Reference Values: 150 – 220mg /dl 
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ESTIMATION OF TRIACYLGLYCEROL  
The tests are performed in the reagent kit by ENZYMATIC 
COLORIMETRIC METHOD. 
Principle : 
Lipoprotein lipase catalyzed hydrolysis of triacylglycerol  yield 
glycerol which is phosphorylated by glycerol kinase using ATP to 
glycerol -3 -phosphate which upon oxidation yields dihydroxy acetone 
phosphate and hydrogen peroxide. The hydrogen peroxide reacts with 
phenolic compound and 4 aminoantipyrine  to form a  coloured 
complex. 
Triacylglycerol + H2O      Lipase            Glycerol + Free Fatty Acids. 
Glycerol + ATP      Glycerol Kinase      Glycerol 3 phosphate + ADP 
Glycerol 3 phosphate + O2  Glycerol phosphate Oxidase  DAP+ H2O2  
H2O2 + 4 – Aminoantipyrine + DHBS      Peroxidase 
  Quinoneimine dye +H2O  
(DAP – Dihydroxy acetone phosphate 
DHBS – 3, 5 Dichloro 2 – hydroxyl benzene sulfonate) 
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The  intensity of the purple coloured complex formed during the 
reaction is directly proportional to the triacylglycerol concentration in 
the sample and it is measured at 500 nm. 
Reagent :                                                                
Reagent 1 (enzymes / chromogen) 
Reagent 1A (Buffer) 
Standard-200mg/dl 
Reconstituted Reagent : 
Dissolve the contents of one bottle of reagent 1 with one bottle 
of reagent 1A. 
Procedure 
 Blank Std Test 
Reagent 1ml 1ml 1ml 
Std - 10µl - 
Sample - - 10µl 
 
Mix well and incubate for 5minutes at 37C and read at 500nm. 
Reference values  : Male    ; 60 - 150 mg/dl 
                                Female ; 40 - 140 mg/dl 
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   ESTIMATION OF HDL CHOLESTEROL 
The tests are performed in the reagent kit by 
PHOSPHOTUNGSTATE METHOD. 
Principle : 
Chylomicrons, VLDL & LDL fractions in serum or plasma are 
separated from HDL by precipitating with phsophotungstic acid and 
magnesium chloride. After centrifugation, the cholesterol in the HDL 
fraction, which remains in the supernatant, is assayed with enzymatic 
cholesterol esterase method. 
Reagents : 
Reagent – 1 (enzymes / Chromogen) 
Reagent    1 A (Buffer) 
Reagent  2 (Precipitating Reagent) Phosphotungstic acid 50 mmol /L 
Magnesium chloride 39 mmol/L 
Standard-50mg/dl 
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Procedure 
1) Precipitation 
Dispense into centrifuge tubes. 
Sample               200µl 
Precipitating reagent               200µl 
 
Mix well centrifuge at 3500 – 4500 rpm for 10 minutes, separate the 
clear supernatant immediately and determine the cholesterol content. 
Procedure 
 Blank Std Test 
Reagent 1ml 1ml 1ml 
Std - 50µl - 
Sample - - 50µl 
 
Mix well and incubate for 5minutes at 370C and read at 500nm. 
Reference values : 40 -70 mg / dl 
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CALCULATED PARAMETERS 
 
Friedwald’s Formula 
      If  TAG  is < 400mg/dl 
   VLDL = TAG   mg/dl  
                     5 
     If  TAG  is > 400mg/dl 
             VLDL = TAG    mg/dl 
                               7 
 
      LDL   =        Total Cholesterol – ( HDL+VLDL) mg/dl 
 
 
 
 
 
 
 
 
50

QUANTITATIVE DETERMINATION OF ALBUMIN   
                           (BCG DYE BINDING METHOD) 
Principle  
Albumin in a buffered solution reacts with the anionic bromo cresol 
green with a dye binding reaction to give a  green colour which is 
measured at 630 nm (600 – 650 nm).The intensity of the colour is 
directly proportional to the concentration of the albumin in the sample. 
Reagents:       Reagent I  -Bromocresolgreen  
Succinic Acid  - 94m mol/L 
Sodium hydroxide  - 10.2 m mol / L 
BCG    - 0.149 m mol/L 
 Procedure 
 Blank Standard Test 
Reagent 1 ml 1 ml 1 ml 
Std - 10µl - 
Sample - - 10µl 
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Add 10 µl of sample to1 ml of reagent, mix , incubate for1 minute at 
room temperature and read at 630 nm. 
 Reference values – 3.5-5 g/dl                    
 
ESTIMATION OF GLUCOSE 
GLUCOSE OXIDASE PEROXIDASE METHOD  
Principle: 
Glucose is oxidized by glucose oxidase to gluconic acid and 
H2O2 with gluconolactone as intermediate. 
                                      Glucose Oxidase 
Glucose + O2 + H2O  
         Gluconic acid+ H2O2 
The enzyme  peroxidase  catalyses  the   oxidative coupling of   
4-aminoantipyrine (4AAP) with phenol to yield a coloured 
quinoneimine complex, with absorbance proportional to the 
concentration of glucose in sample. 
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                              Peroxidase 
H2O2+phenol+4AAP                               Quinoneimine Dye+2H2O                                                                    
                                                                     
Reagent  
Reagent I : Enzyme Reagent 
Glucose oxidase  - > 20000 U/L 
Peroxidase - > 2000 U/L 
Phenol - 10 mmol/L 
Phosphate buffer - 200 mmol/L 
Glucose Standard : 100mg / dl 
Procedure 
 Blank Std Test 
Reagent 1ml 1ml 1ml 
Std - 10µl - 
Sample - - 10µl 
 
Mix & incubate for 15 minutes at 370 C. Read at 520nm.  
Reference values :  Glucose  (Fasting)          -     65 – 110 mg/dl 
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RESULTS AND STATISTICAL ANALYSIS 
A total of 100 subjects were included in the present study. Out 
of   this  100, 50 were under the study group (i.e. patients with CKD) 
and the other 50 were under the control group (i.e. apparently healthy  
individuals). 
Age Distribution among the study and control group :- 
Male and female subjects in the age group of  15  to 75 years 
were included in the study. Both the study and control group were age 
matched. 
Quantitative variable (age) is given as frequency and their 
percentage with the cross – tabulation and Pearson chi-square test in 
the Table-I. 
The cross tabulation and Pearson Chi Square test for sex 
distribution in the study is given in the Table - II 
The  PON activity and the levels of Total Cholesterol, TAG, 
HDL, Glucose, Urea, Creatinine & Albumin were estimated for all the 
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samples collected for the study. VLDL and LDL values were 
calculated. 
The values obtained in both the control and study groups are presented 
in the Master Chart I & II 
The values of serum PON activity of the control & study groups are 
plotted in the Scatter Diagram. 
The values were analyzed and the results are presented in Table III-V. 
Correlation between PON and other variables were analyzed using 
Pearson’ s Correlation Analysis. The results are presented in the Table 
VI. 
The Receiver Operating Characteristic curve is plotted for PON and 
presented in Figure I and area under the curve was analyzed & 
presented in the Table VII. 
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Table –I 
AGE GROUP IN YEARS - CROSS TABULATION 
Age  in 
years 
 Group 
Total P value 
Control Test 
15-35 Count  
 
% with in 
age group 
in yrs. 
 
% within 
group 
20 
 
(57.3%) 
 
 
 
[40.0%] 
19 
 
(48.7%) 
 
 
 
[38.0%] 
39 
 
100% 
 
 
 
39.0% 
 
 
 
 
 
 
 
 
 
 
0.917 
(NS) 
36-55 Count  
 
% with in 
age group 
in yrs. 
 
% within 
group  
19 
 
(47.5%) 
 
 
 
[38.0%] 
21 
 
(52.5%) 
 
 
 
[42.0%] 
40 
 
100% 
 
 
 
40% 
36-55 Count  
 
% with in 
age group 
in yrs. 
 
% within 
group  
11 
 
(52.4 %) 
 
 
 
[22.0%] 
10 
 
(47.6%) 
 
 
 
[20.0%] 
21 
 
100% 
 
 
 
21% 
Total Count 50 50 100 
 
Note :  
1) The value with in (          ) refers to row % 
2) The value with in [          ] refers to column % 
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Table –II 
SEX DISTRIBUTION -CROSS TABULATION 
Sex  Group 
Total P value 
Control Test 
Male Count  
 
% with in 
sex 
 
% within 
group 
33 
 
(49.3%) 
 
 
 
[66.0%] 
34 
 
(50.7%) 
 
 
 
[68.0%] 
67 
 
 
 
 
 
 
 
 
0.832 
(NS) Female Count  
 
% with in 
sex 
 
% within 
group 
17 
 
(51.5%) 
 
 
 
[34.0%] 
16 
 
(48.5%) 
 
 
 
[32.0%)] 
33 
 
 
Total Count 50 50 100 
 
Note :  
1) The value with in (          ) refers to Row % 
2) The value with in [          ] refers to Column % 
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Table –III 
      STUDENT- T TEST FOR DIFFERENCE OF TWO MEANS 
PARAMETERS 
GROUP 
t value P value 
CONTROL TEST 
MEAN SD MEAN SD 
PARAOXONASE                        
U/L 117.38 30.62 46.47 24.45 12.798 
<0.001  
S 
            UREA 
mg/dL 
 
29.34 6.74 94.32 39.41 11.491  <0.001  S 
CREATININE 
           mg/dL 0.80 0.15 7.49 3.77 12.521 
<0.001 
S 
           TOTAL 
   CHOLESTEROL 
          mg/dL 
193.68 40.84 197.46 36.64 0.487 0.627 NS 
           HDL 
          mg/dL 45.30 16.52 30.80 6.96 5.720 
<0.001 
S 
            LDL 
          mg/dL 119.06 33.83 126.36 25.76 1.214 
0.228 
NS 
           VLDL   
          mg/dL 26.42 6.76 41.20 15,82 6.076 
 <0.001   
      S 
            TAG 
          mg/dL 132.28 33.69 207.44 78.84 6.198 
<0.001 
S 
        ALBUMIN  
           g/dL 3.89 0.55 3.49 0.84 2.835 
0.006 
S 
 
S -SIGNIFICANT ; NS- NON SIGNIFICANT. 
 
P  value < 0.05 is Significant 
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Table –IV 
AGE  MATCHED COMPARISON  OF  PON ACTIVITY IN 
THE STUDY AND CONTROL GROUP. 
 
 
Table –V 
SEX MATCHED COMPARISON  OF  PON ACTIVITY IN 
THE  STUDY  AND  CONTROL  GROUP                                                                                                                              
. 
 
SEX Group 
Mean 
U/L 
SD t value ‘P’ value 
MALE 
CONTROL 
STUDY 
117.95 
46.09 
30.60 
24.69 
10.59 
<0.001 
SIGNIFICANT 
FEMALE 
CONTROL 
STUDY 
110.39 
47.26 
38.97 
24.71 
5.517 
<0.001 
SIGNIFICANT 
 
 
AGE 
Group Group 
Mean 
U/L 
SD t value ‘P’ value 
15-35 
CONTROL 
STUDY 
138.38 
52.39 
19.49 
29.71 
10.627 
<0.001 
SIGNIFICANT 
36-55 
CONTROL 
STUDY 
110.83 
47.68 
24.76 
25.98 
7.956 
<0.001 
SIGNIFICANT 
56-75 
CONTROL 
STUDY 
88.46 
42.62 
27.58 
17.99 
4.459 
<0.001 
SIGNIFICANT 
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Table –VI 
PEARSON  CORRELATION  ANALYSIS  OF  PON  
ACTIVITY  WITH  OTHER    VARIABLES. 
 
PARAMETERS CORRELATION CO-EFFICIENT P VALUE 
AGE - 0.233 0.020 S 
UREA -0.679 <0.001 S 
CREATININE -0.659 <0.001 S 
TOTAL 
CHOLESTEROL -0.070 
0.491 
NS 
HDL 0.508 <0.001 S 
LDL -0.179 0.075 NS 
VLDL -0.489 <0.001 S 
TAG -0.254 0.011 S 
ALBUMIN 0.256 0.010 S 
 
 
 
P  value < 0.05 is Significant (S); Non Significant(NS) 
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RECEIVER OPERATING CHARACTERISTIC                           
CURVE FOR PARAOXONASE 
 
 
Table –VII 
AREA UNDER THE CURVE 
 
Area Std Error (a) P Value 
Asymptotic 95% 
Confidence Interval 
Lower Limit Upper Limit 
0.955 0.018 <0.001 0.920 0.990 
 
1 - Specificity
1.00.80.60.40.20.0
Sensitivity
1.0
0.8
0.6
0.4
0.2
0.0
ROC Curve
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DISCUSSION 
 
 
 
The present study establishes the characterization of the PON 
activity for its association in the early prediction of atherosclerosis in 
CKD patients. 
The ability to detect atherogenesis earlier, is necessary for 
taking preventive measures against cardiovascular disease in CKD. 
This study supports the fact that the measurement of PON activity is 
useful in detecting the risk for cardiovascular disease in CKD patients. 
In the present study, the mean age of the control group was 
41.6±13.1yrs and for the study group the mean age was 41.4±13.8 
yrs. The two groups were found to be age-matched using the cross – 
tabulation and Chi-Square tests (p=0.917) ,Table I. 
Similarly, Chi-Square test was performed to find out any 
difference in the male and female composition among the two groups. 
It was found out that the two groups were sex matched (p=0.832) 
Table II. 
62

The Student ‘t’  – test was used to compare the Serum PON 
activity between the two groups. 
The mean value of the Serum PON activity in the study group 
(46.47 + 24.45 U/L) showed a significant  fall of 60.4% compared to 
the mean value of the control group (117.38 ± 30.62 U/L); p= <0.001. 
This study also correlates with the data given in the previous studies 
on Serum PON activity in CKD and there is a significant decrease in 
PON activity in CKD patients 83. 
The mean values of  Serum PON activity between the control 
and study groups in different age groups (15-35 , 36-55 & 56-75 yrs) 
were compared. All of them showed significant decrease in PON 
activity in the study group( p=<0.001), Table IV. 
Similarly the sex matched comparison of PON activity between 
the two groups also showed a significant decrease in PON activity in 
the study group Table V. 
The parameters, Total Cholesterol, TAG, HDL, VLDL & LDL 
(the traditional risk factors used in the prediction of atherosclerosis) 
were  also analyzed  using  Student ‘t’  – test. 
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The   comparison of the mean values of Total cholesterol in the 
study group (197.46 + 36.64 mg/dl) and the control group (193.68 + 
40.84 mg/dl) showed no significant difference. p=0.627. 
The comparison of the mean values of  TAG  in the study group 
(207.44 ±78.85 mg/dl) and the control group (132.28±33.69mg/dl)  
showed a significant increase in the study group. p= <0.001. 
There is a highly significant difference  between the mean 
values of  HDL Cholesterol in the study group (30.80 ± 6.96 mg/dl) 
and the control group (45.30 ± 16.52 mg/dl). The HDL level is 
significantly decreased in the study group. p=<0.001. 
The mean values of LDL  Cholesterol between the study group 
(126.36 + 25.76 mg/dl) and the control group (119.06 + 33.83 mg/dl) 
showed no significant difference. P = 0.228. 
The comparison of the mean values of VLDL Cholesterol  in 
the study group (41.20 + 15.82 mg/dl) and the control group (26.42 + 
6.76mg/dl) showed a significant difference ,with increased levels in 
the study group. P=<0.001. 
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The differences in the levels of these parameters between the 
two   groups  are  associated  with the secondary dyslipidemic changes 
in  CKD. 
Among the other parameters measured, Urea and Creatinine 
levels are significantly increased in the study group with the p value of 
<0.001, while Albumin levels are decreased in the study group. 
In the Pearson’ s Correlation Analysis (Table VII), the PON 
activity is negatively correlating with age in years ( P= 0.020). 
The negative correlation of PON activity with age and the 
comparison study in the age groups shows a possible relation between 
PON activity and age. As age increases PON activity decreases. 
Considering the suspected protective role of PON in atherosclerosis, it 
is interesting to note that aging is accompanied by this reduction in 
enzyme activity. PON activity diminishing with time could be a non-
negligible factor of increased atherosclerosis development in elderly 
people 10. 
The levels of Urea, Creatinine, Total Cholesterol, VLDL and 
TAG are negatively correlating with the PON activity. 
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The HDL Cholesterol  levels had significant positive correlation 
with the PON activity with the p value <0.001. This correlation proves 
the association of PON with HDL.  
The ROC curve of PON activity revealed an area under the 
curve of 0.955 and a standard error of 0.018, showing as asymptotic 
significance of 0.001, proving it as a good early predictor in 
diagnosing cardiovascular events in CKD patients. 
In CKD patients, an increased effect of oxidative stress on LDL 
lipoprotein in vitro has been reported as it had been (84,85,86,) noticed in 
patients with Familial hypercholesterolemia, Diabetes Mellitus or 
Coronary heart disease. This work sustains the relationship between 
low PON activity and diseases with low anti-oxidant defense and 
excessive lipid peroxidation. 
PON plays its protective role in atherogenesis by hydrolyzing 
some products of lipid peroxidation and consequently by limiting LDL 
oxidation and foam cell synthesis. This allows us to hypothesize that 
in uremia, loss of that protection could represent a very important 
factor in atherosclerosis. 
66

In renal failure, the accumulation of Nitrogen derived products 
within the environment of the arterial wall, could decrease PON 
activity by directly inhibiting the enzyme or by modifying its 
synthesis and secretion. 
The intake of nutritional antioxidants such as Vitamin C, 
Carotenoids, (lycopene and beta-carotene) and mainly Polyphenols 
(such as those present in red wine, licorice root ethanolic extract, or in 
pomegranate)48  by atherosclerotic animals and also by CVS patients, 
leads to a reduction in oxidative stress and to the attenuation of 
atherosclerosis development. These latter phenomena could be related 
to the nutritional anti-oxidants induced increase in HDL PON 1 
activity. (effects on gene expression, or preventing enzyme 
inactivation and on increasing PON 1 stability through its  binding to 
HDL)87. 
Thus  by determining  the  PON activity earlier in CKD 
patients,  interventions  can  be  made to  increase the PONS by 
dietary or   pharmacological  means. Thereby we  can reduce  the 
macrophage foam cell formation and attenuate  the development  of  
atherosclerosis  75. 
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CONCLUSION 
 
 
 
This present study, shows the involvement of PON in the 
excessive LDL peroxidation   noticed in uremia. This study presents a 
potential explanation of accelerated atherosclerosis in CKD. 
       There is a significant decrease in PON activity in the CKD 
patients and  thus the decrease of its  anti atherogenic properties in 
renal failure could be an  important  factor  in premature vascular 
aging. 
The introduction of PON is a welcome event and based on the 
results obtained, the present study supports the previous studies that  
PON  is a useful marker for the early diagnosis of atherosclerosis in  
CKD patients. 
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SCOPE FOR FURTHER STUDY 
 
 
 
 Further   studies  can be done  for  comparison  of PON 
activity in CKD patients on conservative  management,    
hemodialysis  and  those who had undergone renal 
transplantation. 
 Studies on determination of PON polymorphisms are needed 
to evaluate the discordance in human PON 1 gene between 
phenotypes and genotypes in CKD. 
 Dietary  determinants of Serum PON activity in  human can 
be studied for the timely intervention. 
 
  
TABLE - 1 
CLASSIFICATION OF CKD 
Stage GFR, mL/min per 1.73 m2 
0 >90 with risk factors for CKD 
1  90 with demonstrated Kidney damage e.g. 
persistant proteinuria, abnormal blood and urine 
chemistry.  
2 60 – 89 
3 30 – 59 
4 15 – 29 
5 < 15 
 
Source :  Modified from National Kidney foundation. K/DOQI clinical 
Practice guidelines for CKD : Evaluation, Classification and 
Stratification. AmJ Kidney Dis 39: Supply 1, 2002. 

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PARAOXONASE 
 
 
 
ReproducedfromWebsite ; 
http://newsimg.bbc.co.uk/media/images/40098000/jpg/_40098839_ 
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       PARAOXONASE & ATHEROSCLEROSIS 
 
Reproduced  from  Website  ; http://www.aviramlipids.com/lipid_ 
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MASTER CHART CONTROL GROUP 
S.No Age SexParaoxonase U/L  
Urea 
mg/dl 
Creatinine 
mg/dl 
Total 
Cholesterol 
mg/dl  
HDL 
mg/dl 
LDL 
mg/dl 
VLDL 
mg/dl  
TGL 
mg/dl 
Albumin 
gm/dl 
Glucose 
mg/dl  
1 56 F 94.8 40 1.1 253 45 186 22 110 3.5 112 
2 37 F 68.1 30 0.6 186 53 98 35 177 4.3 126 
3 56 F 89.5 26 0.9 167 46 106 15 78 4.7 100 
4 38 F 142.6 30 0.6 237 49 167 21 105 4 112 
5 33 F 152.1 28 0.7 210 57 108 45 227 5.5 114 
6 41 F 93 35 0.6 233 40 169 24 121 4.4 127 
7 51 F 89 24 0.7 180 45 110 24 121 3.4 98 
8 38 F 142.9 21 0.9 210 52 132 26 130 3.5 75 
9 24 F 148 18 0.6 160 48 90 22 110 3.8 90 
10 43 F 105.5 36 0.9 194 42 27 25 124 4.3 72 
11 32 F 132.7 18 0.6 170 46 95 29 143 3.6 84 
12 52 F 121.5 27 0.6 199 48 131 20 100 4.2 89 
13 60 F 52.7 24 0.8 200 38 143 18 92 4.5 87 
14 65 F 106.8 40 0.8 160 44 90 26 128 3.4 92 
15 36 F 132.4 23 0.7 169 47 92 30 150 3 109 
16 30 F 148.9 26 0.6 164 47 93 24 120 3 83 
17 26 F 156.2 30 0.8 180 48 108 24 120 3.6 90 
18 45 M 141.5 26 0.7 380 57 209 34 169 4.2 140 
19 57 M 124.8 25 0.8 307 47 209 51 255 4 128 
20 20 M 158.6 25 0.6 147 49 84 14 70 4.8 106 
21 35 M 149.9 38 0.9 220 60 140 16 82 4.3 74 
22 20 M 142.4 28 0.8 156 5 83 22 108 4 106 
23 35 M 95.4 26 0.7 200 145 125 30 150 4 110 
24 50 M 109.5 30 1 220 40 146 34 168 4.5 116 
25 42 M 70.5 34 0.8 175 35 112 28 142 3.6 80 
26 47 M 93 23 0.9 194 42 128 24 120 3.5 110 
27 42 M 102.6 18 1 200 43 135 22 109 3.6 104 
28 40 M 88.5 32 0.9 220 38 155 26 132 4 110 
29 36 M 155.7 20 0.9 174 50 96 30 148 4 100 
30 29 M 145.7 22 1 190 41 127 22 110 4.6 62 
31 54 M 95.6 40 1.2 230 44 156 30 150 3.9 70 
32 56 M 112.8 40 0.6 192 48 118 36 180 3.5 74 
33 62 M 68.1 30 0.7 210 34 135 31 153 3.5 78 
34 45 M 110.6 21 0.7 204 40 140 24 120 3.8 87 
35 45 M 108.7 38 0.8 189 45 114 30 149 3.2 100 
36 70 M 60 49 0.8 200 39 113 34 172 3.3 106 
37 30 M 173 33 0.9 191 45 124 22 110 3.5 92 
38 32 M 138 34 1 169 38 104 27 136 3.8 69 
39 64 M 50.2 26 1 162 32 108 22 110 4 104 
40 28 M 122 35 0.7 149 35 91 23 115 4.2 91 
41 29 M 139 28 0.9 170 40 105 25 126 4.3 108 
42 56 M 88.2 29 0.7 180 37 115 28 140 3.5 116 
43 32 M 123 37 0.8 168 42 96 30 148 3 96 
44 50 M 136.8 29 0.7 159 49 91 19 95 3.1 82 
45 58 M 125.2 35 0.8 184 40 120 24 123 3 120 
46 28 M 142.6 26 0.9 196 41 129 26 132 4.2 119 
47 33 M 109.4 32 0.7 156 39 87 30 152 3.8 112 
48 19 M 156.5 24 0.9 132 48 61 23 116 5 98 
49 49 M 108.6 32 1 220 38 151 31 155 3.8 116 
50 25 M 145.9 26 0.9 168 44 101 23 113 4.5 106 
 
MASTER CHART STUDY GROUP 
S.No Age SexParaoxonase U/L  
Urea 
mg/dl 
Creatinine 
mg/dl 
Total 
Cholesterol 
mg/dl  
HDL 
mg/dl 
LDL 
mg/dl 
VLDL 
mg/dl 
TGL 
mg/dl 
Albumin 
gm/dl 
Glucose 
mg/dl  
1 38 F 21.2 160 7.8 219 28 123 68 348 2.6 116 
2 40 F 59.2 76 4 166 30 105 31 158 4.2 78 
3 22 F 106.9 56 1.9 170 42 101 27 136 3.5 128 
4 72 F 38.3 60 3 220 32 140 48 242 6 120 
5 45 F 36.8 56 12 180 35 119 26 134 2.6 132 
6 60 F 34.7 70 8.4 131 38 64 29 146 3.1 106 
7 35 F 38.9 96 2.8 220 30 133 57 285 2.5 126 
8 62 F 46 106 9 178 32 118 28 140 4 94 
9 32 F 28 84 6.6 200 24 131 45 225 3.2 100 
10 29 F 35 92 6.8 186 31 129 26 128 2.7 116 
11 26 F 54 87 12.4 196 32 127 37 188 3 132 
12 56 F 84 104 9.2 222 22 130 70 350 3 136 
13 52 F 81.2 69 7.6 188 30 121 29 142 3.5 106 
14 56 F 48 71 6.2 192 31 106 37 188 4 88 
15 42 F 19.8 112 12.8 250 25 166 59 296 2.7 110 
16 60 F 24.1 78 14.2 201 26 123 52 262 4 82 
17 36 M 52 155 13.9 170 30 110 30 150 3 78 
18 55 M 59 84 5.6 186 32 128 26 133 5 64 
19 29 M 44 71 7.6 179 27 119 33 167 4 62 
20 40 M 23 86 6.5 220 20 159 41 204 2.7 120 
21 32 M 28.6 158 11.8 220 21 167 33 168 2.8 128 
22 36 M 64 60 6.2 190 42 116 32 160 5 120 
23 46 M 46 66 6.2 259 30 168 61 306 3.2 140 
24 30 M 117 101 11.1 240 45 159 32 182 2.2 136 
25 42 M 98.2 93 9.8 198 47 113 38 190 2.6 142 
26 50 M 87.6 57 5.5 205 40 105 60 299 4 118 
27 34 M 48 60 6.3 108 29 105 46 230 4 78 
28 60 M 46 98 8.4 228 30 146 52 264 5.5 68 
29 47 M 29 90 12.2 198 21 122 55 276 3 150 
30 49 M 31.4 85 13 204 27 143 34 174 2.8 112 
31 24 M 20.3 161 7 139 26 98 15 78 3.7 60 
32 48 M 36.3 124 4.8 130 24 72 34 170 3.7 68 
33 45 M 34.6 82 3.8 235 31 147 57 285 3.2 133 
34 43 M 30.2 53 2.1 238 32 152 54 273 4 130 
35 27 M 47.3 64 2.6 171 38 113 20 101 3.6 120 
36 20 M 22.4 49 1.6 170 39 115 16 82 5.1 110 
37 16 M 36 192 13.6 168 19 119 30 150 3.3 141 
38 20 M 60.7 76 2.5 144 25 99 20 102 2.4 130 
39 32 M 29.7 54 2.8 160 30 92 38 190 2.8 90 
40 60 M 23 140 12 250 29 144 77 384 3.5 142 
41 32 M 69 126 2.4 190 36 124 30 150 3.5 118 
42 62 M 28.1 46 5.6 240 26 143 71 356 4 106 
43 38 M 13.1 106 9.8 190 19 115 56 282 2.9 120 
44 55 M 101.3 62 6 214 48 135 31 156 3.9 96 
45 65 M 54 56 5.8 281 35 173 73 364 3.4 114 
46 15 M 54.2 68 5.5 194 36 134 24 120 3.2 127 
47 35 M 24.8 192 11.8 218 28 155 35 174 2.9 119 
48 40 M 34.2 198 14.5 165 25 91 49 244 3.2 151 
49 35 M 31 112 3.6 272 29 195 48 240 2.8 100 
50 46 M 43.2 114 7.8 180 36 106 40 200 5 72 

